I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Laura Esserman, MD, MBA
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Laura Esserman, MD, MBA
Dr. Laura Esserman, M.D., M.B.A is a surgeon and breast cancer oncology specialist practicing at the UCSF Carol Franc Buck Breast Care Center where she has also held the position of Director since 1996. She co-leads the Breast Oncology Program, the largest of the UCSF Helen Diller Comprehensive Cancer Center's multidisciplinary programs.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- QuantumLeap Healthcare Collaborative
- Links
- I-SPY 2 TRIAL Website Abstract S5-02 SABCC 2014 Abstract CT227 AACR 2014 Abstract P1-14-03; SABCC 2015
- ID
- NCT01042379
- Phase
- Phase 1
- Study Type
- Interventional
- Last Updated